---
title: "ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS | IBRX Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287354540.md"
description: "ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS | IBRX Stock News"
datetime: "2026-05-22T03:30:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287354540.md)
  - [en](https://longbridge.com/en/news/287354540.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287354540.md)
---

# ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS | IBRX Stock News

ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS | IBRX Stock News

### Related Stocks

- [IBRX.US](https://longbridge.com/en/quote/IBRX.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)

## Related News & Research

- [ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026 | IBRX Stock News](https://longbridge.com/en/news/288311834.md)
- [ImmunityBio Highlights Patient Survey Data at ISPOR 2026 Showing Majority of UK Adults Living with NMIBC Favor Bladder Preservation | IBRX Stock News](https://longbridge.com/en/news/287354508.md)
- [ImmunityBio (IBRX) to Release Quarterly Earnings on Monday](https://longbridge.com/en/news/285089039.md)
- [ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors | IBRX Stock News](https://longbridge.com/en/news/279976046.md)
- [ImmunityBio Expands Bladder Cancer Arsenal With Exclusive Japanese BCG Partnership](https://longbridge.com/en/news/286787574.md)